Effects of emotion-oriented interventions on cognitive, behavioral, and psychological symptoms in people with dementia: a systematic review and meta-analysis of randomized controlled trials Authors: Andrea Duarte-Díaz, Yolanda Álvarez-Pérez, Vanesa Ramos-García, Lilisbeth Perestelo-Pérez, Marta Aymerich, Noemí Robles, Carme Carrion Published: 2025 ABSTRACT AbstractBackgroundDementia is a major global health challenge associated with progressive cognitive decline and neuropsychiatric symptoms that greatly affect patients and caregivers. Emotion-oriented interventions (EOIs) are nonpharmacological approaches designed to address not only cognitive deficits but also the emotional and psychological needs of people with dementia.ObjectivesThis systematic review (SR) and meta-analysis (MA) focused on the efficacy of EOIs in dementia care, particularly examining their impact on cognitive, behavioral and psychological symptoms.MethodsA comprehensive search of electronic databases, such as PubMed, EMBASE, CINAHL, PsycINFO, Cochrane, Scopus, and Web of Science, supplemented by manual consultations of reference lists was performed. The inclusion criteria included studies involving people diagnosed with dementia and employing EOIs such as supportive psychotherapy, validation therapy, sensory integration, simulated presence therapy, and reappraisal therapy. Risk of bias assessment utilized the Cochrane risk-of-bias tool, with data synthesis conducted through meta-analyses, incorporating post hoc subgroup analyses and meta-regression to explore variations. Statistical analyses and corrections for publication bias were performed using Stata v17.ResultsThe analysis included 34 randomized controlled trials (RCTs) that compared emotion-oriented interventions such as reminiscence therapy, Snoezelen, and validation therapy against standard care and other therapeutic modalities. The synthesized data indicate that emotion-oriented interventions can significantly improve cognition, depressive symptoms, health-related quality of life and functional abilities, particularly in settings lacking alternative therapeutic options. These interventions also show some potential, although their effectiveness varies compared to that of active controls and depends on the specific intervention and context of the study.ConclusionEmotion-oriented therapies could offer a valuable complement to traditional dementia treatments, especially in resource-limited settings where conventional therapies may not be readily available. These interventions address not only the cognitive deficits but also the emotional and psychological well-being of people with dementia, suggesting a holistic approach to dementia care. The findings highlight the need for further research to optimize these interventions, evaluate their long-term benefits, and establish guidelines for their implementation in diverse clinical settings.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12877-025-06804-w.Keywords: Emotion-oriented interventions, Reminiscence therapy, Snoezelen, Dementia, Systematic review Background Dementia is a complex neurocognitive disorder characterized by a progressive decline in cognitive abilities that interferes with independence in daily functioning. The fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) classifies neurocognitive disorders into three main syndromes: delirium, mild neurocognitive disorder, and major neurocognitive disorder or dementia [1]. Among the different types of dementia, Alzheimer’s disease is the most prevalent, followed by vascular dementia, dementia with Lewy bodies, and mixed forms involving multiple etiologies [2]. Less common types, such as frontotemporal degeneration or dementias related to brain injury, infections, and alcohol abuse, are also recognized [2]. This diversity underscores the multifaceted nature of dementia and the need for comprehensive and individualized care approaches. Dementia represents a growing public health challenge. The World Health Organization (WHO) estimates that over 55 million people currently live with dementia, with nearly 10 million new cases each year [3]. The number of people affected is projected to reach 139 million by 2050 [4], making dementia one of the leading causes of disability and dependency among older adults [5]. Beyond the progressive loss of cognitive and functional abilities experienced by those diagnosed, dementia places a profound emotional, physical, and financial burden on families and caregivers. This condition not only places a strain on personal relationships and resources but also places considerable pressure on societal health and social care systems [6]. The global economic impact of dementia was estimated at approximately US$ 818 billion in 2015. Since then, the annual cost associated with dementia has surged beyond US$ 1.3 trillion, and future projections suggest a steep rise in these costs, with expectations to more than double, reaching US$ 2.8 trillion by 2030 [7]. This dramatic increase is not only indicative of the growing number of people living with dementia but also underscores the extensive demands placed on healthcare and social support systems. Notably, the costs of informal care constitute between 50% and 90% of the total costs for dementia, pointing to the significant burden borne by caregivers and the wider community [8]. Dementia is a multifaceted syndrome characterized by a spectrum of cognitive impairments and notable behavioral and psychological symptoms. The present diagnostic framework for dementia prioritizes cognitive deficits and the gradual deterioration of cognitive functions as its central criteria. However, the scope of cognitive impairment alone falls short in fully accounting for the functional disabilities or diminished quality of life experienced by those with dementia. Beyond cognitive decline, an estimated 80% to 90% of people with dementia experience various noncognitive disturbances throughout the illness [9]. These disturbances, collectively termed behavioral and psychological symptoms of dementia (BPSD), encompass a variety of symptoms, such as apathy, irritability or mood swings, agitation, and unusual motor behaviors, among others [9, 10]. Currently, dementia is a condition without a definitive cure, yet there are available treatments aimed at symptom management. People diagnosed with dementia face multifaceted challenges that span various domains, including cognitive function, neuropsychiatric symptoms, daily living activities, and often, comorbid physical illnesses. Effective interventions require a holistic approach, addressing the cognitive, emotional, psychological, and social needs of the patient [11]. This comprehensive treatment strategy emphasizes the importance of both pharmacological and nonpharmacological interventions for managing cognitive decline and BPSD. A variety of pharmacological treatments, such as antipsychotics, antidepressants, sedative drugs or anxiolytics, are commonly used to address cognitive impairment and BPSD. However, these medications can have significant side effects [12]. As a result, current guidelines recommend initially exploring nonpharmacological interventions before resorting to pharmacological treatments [13, 14]. The American Psychiatric Association (APA) [15] categorizes nonpharmacological treatments for dementia into four distinct types: cognition-oriented treatments (e.g., reality orientation and skills training); behavior-oriented approaches; stimulation-oriented approaches (including activity and recreation therapy); and emotion-oriented approaches. We previously conducted two systematic reviews (SRs) on cognition-oriented approaches [16, 17], and several recent studies on other nonpharmacological treatments for dementia have been conducted. According to the APA, emotion-oriented approaches encompass therapies such as reminisce therapy, validation therapy, simulated presence therapy, and sensory integration. In this review, we consistently use the term “emotion-oriented interventions” (EOIs) to refer to these approaches. Among the EOIs, reminiscence therapy and sensory integration (Snoezelen) are the most frequently evaluated in people with dementia. Snoezelen involves individually tailored sessions during which various sensory perceptions and experiences are stimulated to benefit elderly patients with dementia. Reminiscence therapy aims to improve both intrapersonal and interpersonal functioning through the reliving, structuring, integrating, and exchanging of memories. A previous review highlighted certain beneficial outcomes linked to EOIs for dementia, such as improved social interaction and reduced behavioral problems, but also revealed considerable differences across studies and substantial methodological limitations [18]. These included small sample sizes, lack of control groups, non-randomized or quasi-experimental designs, heterogeneous interventions and outcome measures, and the absence of objective or blinded evaluators, which made cross-study comparisons and firm conclusions difficult [18]. In recent years, the body of research has expanded, particularly through numerous randomized controlled trials focusing on Reminiscence Therapy. Furthermore, digital modalities supported by information and communication technologies have been proposed to potentially enhance the accessibility and effectiveness of these therapies [19]. Nonetheless, inconsistent results regarding its effectiveness for specific outcome measures have been reported [20–22]. The field of dementia care is rapidly evolving, fueled by new research that may shed light on the possible benefits of emotion-oriented strategies. Recent studies, notably additional randomized controlled trials, underscore a growing interest among researchers in exploring the impact of these interventions on dementia care. Therefore, this SR and meta-analysis (MA) aimed to assess the effectiveness of EOIs in managing cognitive, behavioral, and psychological symptoms associated with dementia, integrating recent research to offer a comprehensive overview of their potential to improve dementia care. Methods This SR adhered to the guidelines outlined in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 statement [23] (Additional File 1). The protocol for this SR was registered in the International Prospective Register of Systematic Reviews (PROSPERO) database (ID: CRD42023431625). Search strategy The following electronic databases were consulted from inception to January 19, 2023: PubMed, EMBASE, CINAHL, PsycINFO, the Cochrane Central Register of Controlled Trials, Scopus, and the Web of Science. In addition, we performed a manual consultation of the reference lists of the included articles. We did not search for unpublished/gray literature. The search terms were organized around key terms such as “emotion-oriented approach”, “supportive psychotherapy”, “reminiscence therapy”, “validation therapy”, “sensory integration” and “dementia”. To enhance precision, filters were applied to identify clinical trials (Additional File 2). Additionally, the reference lists of all eligible studies were screened to identify any additional studies aligning with the inclusion criteria. Inclusion and exclusion criteria Studies involving people diagnosed with dementia, irrespective of its etiology (e.g., Alzheimer’s disease, vascular dementia, etc.), were included. Studies including patients with subjective cognitive decline or mild cognitive impairment were considered only if they also included people with dementia and provided separate data for each population. We considered studies that specifically examined EOIs in the care of people with dementia. The selected interventions were those acknowledged by the American Psychological Association [15] as emotion-oriented, including supportive psychotherapy, validation therapy, sensory integration, simulated presence therapy and reminiscence therapy. Any comparator different from EOIs was considered, including passive (e.g., no intervention, waiting list) or active groups (e.g., behavior-oriented or cognitive-oriented interventions, pharmacological treatment). Randomized controlled trials (RCTs) published in either Spanish or English were considered. Conference abstracts, theses and dissertations, letters, commentaries, essays, book chapters, qualitative studies, case studies, study protocols and reviews were excluded. The primary outcomes were cognitive measures (i.e., global cognitive function), functional assessments (i.e., functional abilities, quality of life), affective indicators (i.e., anxiety, depression, apathy) and behavioral symptoms (i.e., agitation, frontal symptoms) related to dementia. Risk of bias assessment The assessment of risk of bias in the included RCTs was conducted using Version 2 of the Cochrane risk-of-bias tool for RCTs (RoB—2) [24]. Two independent reviewers performed the quality assessment, and discrepancies were resolved through discussion and consensus. In cases where consensus was elusive, a third reviewer was consulted to resolve any disagreements. Study selection and data extraction The electronic search results were imported into standardized sheets, and duplicates were systematically removed. Two members of the research team independently conducted an initial review of all titles and abstracts to preselect RCTs that met the inclusion criteria. Subsequently, the full texts of potentially relevant studies were screened for eligibility by two reviewers. Any discrepancies were addressed through discussion and consensus, with the involvement of a third reviewer if needed. Following the screening process, two reviewers independently extracted data from each included RCT using a standardized data extraction form in Microsoft Excel. The data extracted covered the following categories: (1) study identification (author, year, country); (2) study design; (3) characteristics of the population (age, sex, baseline cognitive status); (4) details of the intervention and the comparator; (5) duration of the intervention and follow-up; (6) outcome measures; and (7) main results. Data synthesis When at least two RCTs reported comparable quantitative data for a given outcome, a meta-analysis was performed. When only one study reported a specific outcome, or when data were insufficient or not comparable across studies, the results were summarized narratively (Additional File 4). Meta-analyses were conducted employing the inverse variance method, and the results were visually represented through forest plots. A random effects model utilizing the Sidik‒Jonkman method as the tau estimator was applied for the synthesis of the data. The assessment of statistical heterogeneity among studies was carried out using the Higgins I2 value [25]. Post hoc subgroup analyses were performed to explore variations based on the type of dementia (Alzheimer’s disease vs. different etiologies), age group (younger (70–79) vs. older (80–89)), dementia severity, setting (institutionalized vs. noninstitutionalized), emotion-oriented approach (reminiscence vs. Snoezelen), comparator and type of control (active vs. passive control). In instances where more than ten studies with relevant data were available, univariate meta-regression analyses were conducted to evaluate the possible moderating effects of age and sex (expressed as the percentage of females) and baseline Mini-Mental State Examination (MMSE) score. Furthermore, for meta-analyses comprising more than ten studies, we assessed publication bias using Egger’s test. To address potential funnel plot asymmetry, the trim-and-fill method was applied for correction. All the statistical analyses were performed using Stata v17. Results The initial electronic database search produced 3850 references. Following the removal of duplicates, a total of 1934 records were screened based on title and abstract. Subsequently, 84 full-text articles were assessed for eligibility. Ultimately, 34 RCTs met the inclusion criteria [26–59]. A visual representation of the study selection process is illustrated in Fig. 1. PRISMA flow diagram Characteristics of the included studies The synthesized dataset included 34 RCTs investigating the effectiveness of various EOIs for people with different forms of dementia. Sample sizes varied substantially across studies, ranging from 18 to 653 participants. The mean age of participants ranged from 71 to 89 years, and the proportion of women also showed considerable variability. Most studies included people with mild-to-moderate dementia, with a mean baseline MMSE score of 17.21 (range: 5–25). Dementia diagnosis was generally established according to standardized clinical criteria (e.g., DSM-IV, ICD-10) or confirmed by a neurologist, geriatrician or psychiatrist. The EOIs assessed in the included studies covered several therapeutic modalities. Reminiscence therapy typically involved guided recall of past experiences using personal photographs, music, or familiar objects, conducted individually or in groups to stimulate memory, identity, and social interaction. Validation therapy emphasized empathetic communication and the acknowledgment of the person’s feelings and perceptions as valid, aiming to enhance emotional well-being. Sensory integration (Snoezelen) provided controlled multisensory stimulation (e.g., lights, sounds) to promote relaxation and reduce behavioral symptoms. These interventions varied in duration, frequency, and delivery format across studies. The control groups included no intervention, usual care, activity sessions, and other therapeutic modalities. Geographically, the studies showcased a global perspective, with studies conducted in diverse countries, including Argentina (n = 1), Belgium (n = 2), Canada (n = 1), China (n = 1), Denmark (n = 1), France (n = 1), Greece (n = 3), Ireland (n = 1), Japan (n = 2), Portugal (n = 1), Spain (n = 4), Sweden (n = 1), Taiwan (n = 8), Turkey (n = 3), the United Kingdom (n = 3) and the United States (n = 1). A complete description of the study characteristics is provided in Table 1. Table 1Main characteristics of included studies (Listed Alphabetically)First author (year), countryDesignSample characteristicsIntervention detailsControl(s)OutcomesLength of intervention and measurement timeAmieva (2016), FranceRCT (individually randomized, parallel-group trial)N = 653Alzheimer Disease (Mild to moderate)NoninstitutionalizedMean age: 78.7 (6.7)Females: 49%MMSE: 21.5Reminiscence Therapy: N = 172Group sessionsWeekly sessions (90 min) during the first three months Maintenance sessions every six weeks for the next 21 monthsCognitive training group: N = 170Individualized cognitive rehabilitation: N = 157Usual Care: N = 154• Apathy (AI)• Behavioral symptoms (NPI)• Cognition (ADAS-COG)• Depressive symptoms (MADRS)• Functional Abilities (DAD)• Quality of life (QoL-AD)24 months3 months (during treatment) and 24 months (postintervention)Baker (1997), UKRCT (individually randomized, parallel-group trial)N = 31Alzheimer Disease and Vascular dementia (Moderate to Severe)NoninstitutionalizedMean age: NRFemales: 48%MMSE: NRSnoezelen: N = NRIndividual sessionsTwice-weekly sessions of 30 min over 4 weeksActivity sessions: N = NR• Behavioral symptoms (BRS) 1• Cognition (MMSE) 14 weeksAfter four sessions (during treatment), after eight sessions (posttreatment) and one-month later (follow-up)Baker (2003), UK, The Netherlands, SwedenRCT (individually randomized, parallel-group trial)N = 136Different types of dementia(Moderate to Severe)UK: NoninstitutionalizedThe Netherlands: InstitutionalizedMean age: NRFemales: NRMMSE: NRSnoezelen: N = 65Individual sessionsTwice-weekly sessions of 30 min over 4 weeksActivity sessions: N = 71• Behavioral symptoms (BRS)• Cognition (MMSE)4 weeksAfter four sessions (during treatment), after eight sessions (posttreatment) and one-month later (follow-up)Charlesworth (2016), UKRCT (individually randomized, parallel-group trial)N = 291Different types of dementia(Any severity)NoninstitutionalizedMean age: 80Females: 53%MSSE: 17.3Reminiscence Therapy: N = 97Group sessionsTwelve weekly sessions of 2 h. Monthly sessions continued for 7 months, giving a possible 19 sessions over 10 months.Carer Supporter Program: N = 48Carer Supporter Program + Reminiscence Therapy: N = 97Usual care: N = 47• Quality of life (QoL-AD, EQ-5D, DEMQOL) 110 months12 months (follow-up)Dimitrou (2022a), GreeceRCT (crossover trial)N = 60Different types of dementia(Any severity)NoninstitutionalizedMean age: 73.40Females: 60%MMSE: 18.22Reminiscence Therapy: N = 60Individual sessionsOnce-a-day sessions of 60 min for five days a week during 3 weeks. Wash-out period: 2 daysMusic Therapy: N = 60Physical Exercise: N = 60• Behavioral symptoms (NPI) 13 weeksThe sixth day of each week (during treatment and posttreatment)Dimitrou (2022b), GreeceRCT (crossover trial)N = 60Different types of dementia(Any severity)NoninstitutionalizedMean age: 71.4Females: 55%MMSE: 17.75Validation Therapy: N = 60Individual sessionsOnce-a-day sessions of 60 min for five days a week during 3 weeks. Wash-out period: 2 daysPsycho-educational program: N = 60Aromatherapy massage: N = 60Music Therapy: N = 60• Behavioral symptoms (NPI) 13 weeksThe sixth day of each week (during treatment and posttreatment)Duru (2016), TurkeyRCT (individually randomized, parallel-group trial)N = 62Alzheimer Disease(Mild to moderate)InstitutionalizedMean age: 82.1Females: 68%MMSE: 14.91Reminiscence Therapy: N = 31Individual sessionsOnce-a-week sessions of 30–45 min during 12 weeks.No intervention (conversation): N = 31• Cognition (MMSE)• Depression (GDS)12 weeks12 weeks (postintervention)Hsiao (2020), TaiwanRCT (individually randomized, parallel-group trial)N = 54Different types of dementia(Mild to Severe)InstitutionalizedMean age: NRFemales: 65%MMSE: NRReminiscence Therapy: N = 22Group sessionsWeekly sessions of 50 min during 12 weeksArt Therapy: N = 24Usual Care: N = 8• Agitation (CMAI)12 weeks1 and 6 weeks after intervention (follow-up)Hsieh (2010), TaiwanRCT (individually randomized, parallel-group trial)N = 61Different types of dementia(Mild to moderate)InstitutionalizedMean age: 77.56Females: 41%MMSE: NRReminiscence Therapy: N = 29Group sessionsWeekly sessions of 40–50 min during 12 weeksNo intervention: N = 32• Apathy (AES-C)• Depression (GDS)12 weeks12 weeks (postintervention)Inel (2019), TurkeyRCT (individually randomized, parallel-group trial)N = 32Alzheimer Disease(Mild to moderate)InstitutionalizedMean age: 74.4Females: 43.8%MMSE: 21.56Internet-Based Reminiscence Therapy: N = 16Group sessionsWeekly sessions of 60 min over a 12-week periodNo intervention (Unstructured Social Interview): N = 16• Apathy (ARS)• Cognition (MMSE)12 weeks12 weeks (postintervention)Justo-Henriques (2021), PortugalRCT (individually randomized, parallel-group trial)N = 251Different types of dementia(Mild to moderate)NoninstitutionalizedMean age: 82.75Females: 72.5MMSE: 21.34Reminiscence Therapy: N = 131Individual sessions26 sessions of 50 min, twice-a-week over 13 weeksUsual Care: N = 120• Cognition (MMSE)• Depression (GDS)• Executive functions (FAB)• Quality of life (QoL-AD)13 weeks13 weeks (postintervention)Kirk (2019), DenmarkRCT (individually randomized, parallel-group trial)N = 50Alzheimer Disease(Mild to moderate)NoninstitutionalizedMean age: 80.02Females: 68%MMSE: 20.02Reminiscence Therapy: N = 22Group sessionsWeekly sessions of 90 min over 5 weeksUsual Care: N = 22• Cognition (ACE) 1• Executive functions (FAB) 15 weeks5 weeks (postintervention)Li (2020), ChinaRCT (individually randomized, parallel-group trial)N = 90Different types of dementia(Mild to moderate)InstitutionalizedMean age: 83.36Females: 45%MMSE: NRReminiscence Therapy: N = 45Group sessionsTwice-weekly sessions of 30 to 45 min over 12 weeksUsual Care: N = 45• Anxiety (NPI)• Behavioral symptoms (NPI)• Cognition (ADAS-Cog)• Depression (CSDD)• Functional capacity (BI)12 weeks4 weeks (during treatment), 12 weeks (postintervention) and 24 weeks (follow-up)Lök (2018), TurkeyRCT (individually randomized, parallel-group trial)N = 60Alzheimer Disease(Mild to moderate)InstitutionalizedMean age: NRFemales: 56.7%MMSE: 18.55Reminiscence Therapy: N = 30Group sessionsWeekly sessions of 60 min over 8 weeksNo intervention: N = 30• Cognition (MMSE)• Depression (CSDD)• Quality of life (QOL-AD)8 weeks8 weeks (postintervention)Maseda (2014), SpainRCT (individually randomized, parallel-group trial)N = 30Different types of dementia(Mild to moderate)InstitutionalizedMean age: 87.3Females: 90MMSE: NRSnoezelen: N = 10Individual sessionsTwice-weekly sessions of 30 min over 16 weeksActivity Group: N = 10No intervention: N = 10• Agitation (CMAI) 1• Behavioral symptoms (NPI) 1• Depression (CSDD) 1• Cognition (MMSE) 1• Functional capacity (BI) 116 weeks16 weeks (postintervention) and 8-week follow-upMaseda (2018), SpainRCT (individually randomized, parallel-group trial)N = 21Different types of dementia(Severe)InstitutionalizedMean age: 88.90Females: 71.4%MMSE: NRSnoezelen: N = 10Individual sessionsTwice-weekly sessions of 30 min over 12 weeksMusic Therapy: N = 11• Anxiety (INTERACT-SHORT)• Depression (INTERACT-SHORT)12 weeks12 weeks (postintervention)Milev (2008), CanadaRCT (individually randomized, parallel-group trial)N = 18Different types of dementia(Mild to Severe)InstitutionalizedMean age: 84.4Females: 83%MMSE: 4.98Snoezelen: N = 5Individual sessions: one session per week over 12 weeksSnoezelen: N = 7Individual sessions: three sessions per week over 12 weeksUsual Care: N = 6• Cognition (MMSE)12 weeks4 and 8 weeks (during intervention); 12 weeks (postintervention) and 24 weeks (follow-up)Nakamae (2014), JapanRCT (individually randomized, parallel-group trial)N = 36Different types of dementia(Mild to Severe)InstitutionalizedMean age: 86Females: 100%MMSE: NRReminiscence Therapy: N = 17Group sessionsSix consecutive, 40-minute weekly sessionsNo intervention: N = 19• Depression (CSDD)• Cognition (MMSE)6 weeks6 weeks (postintervention)O’Shea (2014), IrelandRCT (individually randomized, parallel-group trial)N = 304Different types of dementia(Moderate)InstitutionalizedMean age: 85.4Females: 69MMSE: 12.3Reminiscence Therapy: N = 153Group sessionsAt least four sessions per weekUsual Care: N = 151• Agitation (CMAI)• Depression (CSDD)• Quality of life (QOL-AD)18–22 weeks18–22 weeks (postintervention)Sánchez (2016a), SpainRCT (individually randomized, parallel-group trial)N = 32Different types of dementia(Severe)InstitutionalizedMean age: 85.4Females: 78%MMSE: NRSnoezelen: N = 11Individual sessionsTwice-weekly sessions of 30 min over 16 weeksActivity sessions: N = 11Usual Care: N = 10• Agitation (CMAI) 1• Behavioral symptoms (NPI) 1• Cognition (MMSE) 1• Depression (CSDD) 116 weeks16 weeks (postintervention)Sánchez (2016b), SpainRCT (individually randomized, parallel-group trial)N = 22Different types of dementia(Severe)InstitutionalizedMean age: 88.41Females: 68%MMSE: NRSnoezelen: N = 11Individual sessionsTwice-weekly sessions of 30 min over 16 weeksMusic Therapy: N = 11• Agitation (CMAI) 1• Depression (CSDD) 1• Anxiety (RAID) 1• Cognition (MMSE) 116 weeks16 weeks (postintervention)Serrani (2012), ArgentinaRCT (individually randomized, parallel-group trial)N = 132Alzheimer Disease(Mild-to-Moderate)InstitutionalizedMean age: 85.8Females: 64MMSE: 13.97Reminiscence Therapy: N = 44Individual sessionsTwice-weekly sessions of 60 min over 12 weeksCounseling: N = 44No intervention: N = 44• Functional capacity (ADL)• Quality of life (SRQoL)12 weeks12 weeks (postintervention) and 6 months (follow-up)Su (2012), TaiwanRCT (individually randomized, parallel-group trial)N = 102Different types of dementia(Mild)InstitutionalizedMean agea: 76.2Femalesa: 62.4MMSEa: 25.1Reminiscence Therapy: N = 51Individual sessionsThree-sessions of 120 min per week over 24 weeksNo intervention (support interview): N = 51• Cognition (MMSE)• Depression (GDS)24 weeks24 weeks (postintervention)Tadaka (2007), JapanRCT (individually randomized, parallel-group trial)N = 60Alzheimer Disease and vascular dementia(Mild to Moderate)NoninstitutionalizedMean age: 81.85 (AD), 84.25 (VD)Females: 75% (AD), 67% (VD)MMSE: 14.75 (AD); 19 (VD)Reminiscence Therapy: N = 30Group sessionsWeekly sessions of 60–90 min over 8 weeksUsual Care: N = 30• Cognition (MMSE)• Depression (MOSES)8 weeks8 weeks (postintervention) and 6 months (follow-up)Tatiana-Danai (2022), GreeceRCT (crossover trial)N = 60Different types of dementia(Any severity)NoninstitutionalizedMean age: 75.83Females: 52%MMSE: 17.47Validation Therapy: N = 60Reminiscence Therapy: N = 60Individual sessionsOnce-a-day sessions of 60 min for five days a week during 3 weeksWash-out period: 2 daysPsycho-educational program: N = 60Music Therapy: N = 60• Behavioral symptoms (NPI) 13 weeksThe sixth day of each week (during treatment and posttreatment)Tz-Han (2022), TaiwanRCT (individually randomized, parallel-group trial)N = 45Different types of dementia(Mild to Moderate)NoninstitutionalizedMean age: 82.8Females: 80%MMSE: NRReminiscence Therapy: N = 25Individual sessionsTwice-weekly sessions of 60 min over 4 weeksUsual Care: N = 20• Behavioral symptoms (NPI)• Cognition (SPMSQ)• Depression (CSDD)4 weeks4 weeks (postintervention)Van Bogaert (2013), BelgiumRCT (individually randomized, parallel-group trial)N = 82Alzheimer Disease(Mild to Moderate)InstitutionalizedMean age: 84Females: 83%MMSE: 18.33Reminiscence Therapy: N = 41Individual sessionsWeekly sessions of 45 min over 4 weeksNo intervention: N = 41• Behavioral symptoms (NPI)• Cognition (MMSE)• Depression (GDS)• Executive functions (FAB)4 weeks4 weeks (postintervention)Van Bogaert (2016), BelgiumRCT (individually randomized, parallel-group trial)N = 72Different types of dementia(Mild to Moderate)InstitutionalizedMedian age: 84Females: 80MMSE: NRReminiscence Therapy: N = 36Individual sessionsTwice a week during 8 weeks (45 min)No intervention = 36• Depression (CSDD) 1• Cognition (MMSE) 1• Behavioral symptoms (NPI) 19 weeks9 weeks (postintervention)Wang (2007), TaiwanRCT (individually randomized, parallel-group trial)N = 102Different types of dementia(Mild to Severe)InstitutionalizedMean age: 79.34Females: 51%MMSE: 15.21Reminiscence Therapy: N = 51Group sessionsWeekly sessions of 60 min over 8 weeksUsual Care: N = 51• Cognition (MMSE)• Depression (CSDD)8 weeks8 weeks (postintervention)Wang (2009), TaiwanRCT (individually randomized, parallel-group trial)N = 77Different types of dementia(Mild to Moderate)InstitutionalizedMean age: 79.04Females: 48,1MMSE: NRReminiscence Therapy: N = 38Group sessionsWeekly sessions of 60 min over 8 weeksUsual Care: N = 39• Functional capacity (BI)• Behavioral symptoms (CAPE-BRS)8 weeks8 weeks (postintervention)Woods (2016), UKRCT (individually randomized, parallel-group trial)N = 48Different types of dementia(Mild to Moderate)NoninstitutionalizedMean age: 77.4Females: 49.2MMSE: NRReminiscence Therapy: N = 268Group sessionsWeekly sessions of 120 min over 12 weeks and monthly maintenance sessions for further seven monthsUsual Care: N = 219• Anxiety (RAID)1• Depression (CSDD)1• Functional capacity (BADLS)1• Quality of life (QoL-AD, EQ-5D)112 weeks3 months (postintervention) and 10 months (follow-up)Wu (2016), TaiwanRCT (individually randomized, parallel-group trial)N = 103Different types of dementia(Mild to Moderate)NoninstitutionalizedMean age: 73.6Females: 69%MMSE: 23Reminiscence Therapy: N = 53Group sessionsWeekly sessions of 60 min over 6 weeksNo intervention (interviews): N = 50• Cognition (MMSE)6 weeks6 weeks (postintervention)Yang (2016), TaiwanRCT (individually randomized, parallel-group trial)N = 102Different types of dementia(Mild to Severe)InstitutionalizedMean age: 80.1Females: 66%MMSE: NRReminiscence Therapy: N = 43Group sessionsWeekly sessions of 30 min over 10 weeksCognitive Stimulation: N = 20Aromatherapy: N = 29• Agitation (CMAI)• Depression (CSDDC)10 weeks10 weeks (postintervention)Yu (2019), USARCT (individually randomized, parallel-group trial)N = 80Different types of dementia(Any severity)NoninstitutionalizedMean age: 82.1Females: 58%MMSE: 17.5Reminiscence Therapy: N = 32Individual sessionsTwice-weekly sessions of 30 min over 6 weeksReminiscence Therapy: N = 32Group sessionsTwice-weekly sessions of 30 min over 6 weeksUsual Care: N = 16• Quality of life (QoL ladder)• Behavioral symptoms (NPI)12 weeks12 weeks (postintervention)ABMI Agitation Behavior Mapping Instrument, ADAS-COG Alzheimer Disease Assessment Scale-Cognitive, ABMI The Agitation Behavior Mapping Instrument, ACE-R Addenbrooke’s Cognitive Examination Revised, AD Alzheimer Disease, ADAS-Cog Alzheimer Disease Assessment Scale-Cognitive, ADCS-ADL Alzheimer’s Disease Cooperative Study—Activities of Daily Living Inventory, AGGIR Grille d’Autonomie Gérontologique-Groupes Iso-Ressources, AI Apathy Inventory, AMI Autobiographical Memory Interview, AMS Alzheimer’s Disease and Related Dementia Mood Scale, ARS Apathy Rating Scale, BADLS The Bristol Activities of Daily Living Scale, BANS-S Bedford Alzheimer Nursing Severity, BI Barthel Index, BMD Mood Disturbance Scale, BRS Behavior Rating Scale, CAPE Clifton Assessment Procedures for the Elderly, CAPE-BRS Clifton Assessment Procedures for the Elderly Behavior Rating Scale, CDR Clinical Dementia Rating Scale, CGI Clinical Global Impression, CMAI Cohen-Mansfield Agitation Inventory, CPS Cognitive Performance Scale, CSDD The Cornell Scale For Depression in Dementia, DAD Disablement Assessment for Dementia DEMQOL Dementia Quality of Life Instrument, DLAO The Daily Living Activities Observation, DOS Daily Observation Scale, EQ-5D European Quality of Life-5 Dimensions, FAB Frontal Assessment Battery, FRSSD Functional Rating Scale for Symptoms in Dementia, FRT Functional Reach Test, GAI Geriatric Anxiety Inventory, GCCT The Galton-Crovitz task, GDS Geriatric Scale of Depression, HADS Hospital Anxiety and Depression Scale, HHI Hert Hope Index, IS Interact Scale, LSL Life Satisfaction Scale, MADRS Montgomery-Asberg Depression Rating Scale, MAT Memory Alteration Test, MMSE Mini-Mental State Examination;MOSES Multidimensional Observation Scale for Elderly Subjects, NPI Neuropsychiatric Inventory, NR Not Reported, PES-AD The Pleasant Events Schedule.QCPR Quality of Caregiver–Patient Relationship, QoL Ladder Cantril Quality of Life Ladder, QoL-AD Quality of Life - Alzheimer’s Disease Scale, RAID Rating Anxiety in Dementia, RAVLT Rey Auditory Verbal Learning Test, SIWB Spirituality Index of Well-Being, SPMSQ Short Portable Mental State Questionnaire, SR Sharpened Romberg, TORS Todai-Shiki Observational Rating Scale, TUGT Timed Up and Go Test, UK United Kingdom, USA United States of America, VAS Visual Analog Scale, VD Vascular Dementia, VI Vitality Index, WAIS-III Wechsler Adult Intelligence Scale, ZBI Zarit Burden Interview1Narrative synthesisaSociodemographic and clinical information reported only for patients included in the analyses. Main characteristics of included studies (Listed Alphabetically) N = 653 Alzheimer Disease (Mild to moderate) Noninstitutionalized Mean age: 78.7 (6.7) Females: 49% MMSE: 21.5 Reminiscence Therapy: N = 172 Group sessions Weekly sessions (90 min) during the first three months Maintenance sessions every six weeks for the next 21 months Cognitive training group: N = 170 Individualized cognitive rehabilitation: N = 157 Usual Care: N = 154 • Apathy (AI) • Behavioral symptoms (NPI) • Cognition (ADAS-COG) • Depressive symptoms (MADRS) • Functional Abilities (DAD) • Quality of life (QoL-AD) 24 months 3 months (during treatment) and 24 months (postintervention) N = 31 Alzheimer Disease and Vascular dementia (Moderate to Severe) Noninstitutionalized Mean age: NR Females: 48% MMSE: NR Snoezelen: N = NR Individual sessions Twice-weekly sessions of 30 min over 4 weeks • Behavioral symptoms (BRS) 1 • Cognition (MMSE) 1 4 weeks After four sessions (during treatment), after eight sessions (posttreatment) and one-month later (follow-up) N = 136 Different types of dementia (Moderate to Severe) UK: Noninstitutionalized The Netherlands: Institutionalized Mean age: NR Females: NR MMSE: NR Snoezelen: N = 65 Individual sessions Twice-weekly sessions of 30 min over 4 weeks • Behavioral symptoms (BRS) • Cognition (MMSE) 4 weeks After four sessions (during treatment), after eight sessions (posttreatment) and one-month later (follow-up) N = 291 Different types of dementia (Any severity) Noninstitutionalized Mean age: 80 Females: 53% MSSE: 17.3 Reminiscence Therapy: N = 97 Group sessions Twelve weekly sessions of 2 h. Monthly sessions continued for 7 months, giving a possible 19 sessions over 10 months. Carer Supporter Program: N = 48 Carer Supporter Program + Reminiscence Therapy: N = 97 Usual care: N = 47 10 months 12 months (follow-up) N = 60 Different types of dementia (Any severity) Noninstitutionalized Mean age: 73.40 Females: 60% MMSE: 18.22 Reminiscence Therapy: N = 60 Individual sessions Once-a-day sessions of 60 min for five days a week during 3 weeks. Wash-out period: 2 days Music Therapy: N = 60 Physical Exercise: N = 60 3 weeks The sixth day of each week (during treatment and posttreatment) N = 60 Different types of dementia (Any severity) Noninstitutionalized Mean age: 71.4 Females: 55% MMSE: 17.75 Validation Therapy: N = 60 Individual sessions Once-a-day sessions of 60 min for five days a week during 3 weeks. Wash-out period: 2 days Psycho-educational program: N = 60 Aromatherapy massage: N = 60 Music Therapy: N = 60 3 weeks The sixth day of each week (during treatment and posttreatment) N = 62 Alzheimer Disease (Mild to moderate) Institutionalized Mean age: 82.1 Females: 68% MMSE: 14.91 Reminiscence Therapy: N = 31 Individual sessions Once-a-week sessions of 30–45 min during 12 weeks. • Cognition (MMSE) • Depression (GDS) 12 weeks 12 weeks (postintervention) N = 54 Different types of dementia (Mild to Severe) Institutionalized Mean age: NR Females: 65% MMSE: NR Reminiscence Therapy: N = 22 Group sessions Weekly sessions of 50 min during 12 weeks Art Therapy: N = 24 Usual Care: N = 8 12 weeks 1 and 6 weeks after intervention (follow-up) N = 61 Different types of dementia (Mild to moderate) Institutionalized Mean age: 77.56 Females: 41% MMSE: NR Reminiscence Therapy: N = 29 Group sessions Weekly sessions of 40–50 min during 12 weeks • Apathy (AES-C) • Depression (GDS) 12 weeks 12 weeks (postintervention) N = 32 Alzheimer Disease (Mild to moderate) Institutionalized Mean age: 74.4 Females: 43.8% MMSE: 21.56 Internet-Based Reminiscence Therapy: N = 16 Group sessions Weekly sessions of 60 min over a 12-week period • Apathy (ARS) • Cognition (MMSE) 12 weeks 12 weeks (postintervention) N = 251 Different types of dementia (Mild to moderate) Noninstitutionalized Mean age: 82.75 Females: 72.5 MMSE: 21.34 Reminiscence Therapy: N = 131 Individual sessions 26 sessions of 50 min, twice-a-week over 13 weeks • Cognition (MMSE) • Depression (GDS) • Executive functions (FAB) • Quality of life (QoL-AD) 13 weeks 13 weeks (postintervention) N = 50 Alzheimer Disease (Mild to moderate) Noninstitutionalized Mean age: 80.02 Females: 68% MMSE: 20.02 Reminiscence Therapy: N = 22 Group sessions Weekly sessions of 90 min over 5 weeks • Cognition (ACE) 1 • Executive functions (FAB) 1 5 weeks 5 weeks (postintervention) N = 90 Different types of dementia (Mild to moderate) Institutionalized Mean age: 83.36 Females: 45% MMSE: NR Reminiscence Therapy: N = 45 Group sessions Twice-weekly sessions of 30 to 45 min over 12 weeks • Anxiety (NPI) • Behavioral symptoms (NPI) • Cognition (ADAS-Cog) • Depression (CSDD) • Functional capacity (BI) 12 weeks 4 weeks (during treatment), 12 weeks (postintervention) and 24 weeks (follow-up) N = 60 Alzheimer Disease (Mild to moderate) Institutionalized Mean age: NR Females: 56.7% MMSE: 18.55 Reminiscence Therapy: N = 30 Group sessions Weekly sessions of 60 min over 8 weeks • Cognition (MMSE) • Depression (CSDD) • Quality of life (QOL-AD) 8 weeks 8 weeks (postintervention) N = 30 Different types of dementia (Mild to moderate) Institutionalized Mean age: 87.3 Females: 90 MMSE: NR Snoezelen: N = 10 Individual sessions Twice-weekly sessions of 30 min over 16 weeks Activity Group: N = 10 No intervention: N = 10 • Agitation (CMAI) 1 • Behavioral symptoms (NPI) 1 • Depression (CSDD) 1 • Cognition (MMSE) 1 • Functional capacity (BI) 1 16 weeks 16 weeks (postintervention) and 8-week follow-up N = 21 Different types of dementia (Severe) Institutionalized Mean age: 88.90 Females: 71.4% MMSE: NR Snoezelen: N = 10 Individual sessions Twice-weekly sessions of 30 min over 12 weeks • Anxiety (INTERACT-SHORT) • Depression (INTERACT-SHORT) 12 weeks 12 weeks (postintervention) N = 18 Different types of dementia (Mild to Severe) Institutionalized Mean age: 84.4 Females: 83% MMSE: 4.98 Snoezelen: N = 5 Individual sessions: one session per week over 12 weeks Snoezelen: N = 7 Individual sessions: three sessions per week over 12 weeks 12 weeks 4 and 8 weeks (during intervention); 12 weeks (postintervention) and 24 weeks (follow-up) N = 36 Different types of dementia (Mild to Severe) Institutionalized Mean age: 86 Females: 100% MMSE: NR Reminiscence Therapy: N = 17 Group sessions Six consecutive, 40-minute weekly sessions • Depression (CSDD) • Cognition (MMSE) 6 weeks 6 weeks (postintervention) N = 304 Different types of dementia (Moderate) Institutionalized Mean age: 85.4 Females: 69 MMSE: 12.3 Reminiscence Therapy: N = 153 Group sessions At least four sessions per week • Agitation (CMAI) • Depression (CSDD) • Quality of life (QOL-AD) 18–22 weeks 18–22 weeks (postintervention) N = 32 Different types of dementia (Severe) Institutionalized Mean age: 85.4 Females: 78% MMSE: NR Snoezelen: N = 11 Individual sessions Twice-weekly sessions of 30 min over 16 weeks Activity sessions: N = 11 Usual Care: N = 10 • Agitation (CMAI) 1 • Behavioral symptoms (NPI) 1 • Cognition (MMSE) 1 • Depression (CSDD) 1 16 weeks 16 weeks (postintervention) N = 22 Different types of dementia (Severe) Institutionalized Mean age: 88.41 Females: 68% MMSE: NR Snoezelen: N = 11 Individual sessions Twice-weekly sessions of 30 min over 16 weeks • Agitation (CMAI) 1 • Depression (CSDD) 1 • Anxiety (RAID) 1 • Cognition (MMSE) 1 16 weeks 16 weeks (postintervention) N = 132 Alzheimer Disease (Mild-to-Moderate) Institutionalized Mean age: 85.8 Females: 64 MMSE: 13.97 Reminiscence Therapy: N = 44 Individual sessions Twice-weekly sessions of 60 min over 12 weeks Counseling: N = 44 No intervention: N = 44 • Functional capacity (ADL) • Quality of life (SRQoL) 12 weeks 12 weeks (postintervention) and 6 months (follow-up) N = 102 Different types of dementia (Mild) Institutionalized Mean agea: 76.2 Femalesa: 62.4 MMSEa: 25.1 Reminiscence Therapy: N = 51 Individual sessions Three-sessions of 120 min per week over 24 weeks • Cognition (MMSE) • Depression (GDS) 24 weeks 24 weeks (postintervention) N = 60 Alzheimer Disease and vascular dementia (Mild to Moderate) Noninstitutionalized Mean age: 81.85 (AD), 84.25 (VD) Females: 75% (AD), 67% (VD) MMSE: 14.75 (AD); 19 (VD) Reminiscence Therapy: N = 30 Group sessions Weekly sessions of 60–90 min over 8 weeks • Cognition (MMSE) • Depression (MOSES) 8 weeks 8 weeks (postintervention) and 6 months (follow-up) N = 60 Different types of dementia (Any severity) Noninstitutionalized Mean age: 75.83 Females: 52% MMSE: 17.47 Validation Therapy: N = 60 Reminiscence Therapy: N = 60 Individual sessions Once-a-day sessions of 60 min for five days a week during 3 weeks Wash-out period: 2 days Psycho-educational program: N = 60 Music Therapy: N = 60 3 weeks The sixth day of each week (during treatment and posttreatment) N = 45 Different types of dementia (Mild to Moderate) Noninstitutionalized Mean age: 82.8 Females: 80% MMSE: NR Reminiscence Therapy: N = 25 Individual sessions Twice-weekly sessions of 60 min over 4 weeks • Behavioral symptoms (NPI) • Cognition (SPMSQ) • Depression (CSDD) 4 weeks 4 weeks (postintervention) N = 82 Alzheimer Disease (Mild to Moderate) Institutionalized Mean age: 84 Females: 83% MMSE: 18.33 Reminiscence Therapy: N = 41 Individual sessions Weekly sessions of 45 min over 4 weeks • Behavioral symptoms (NPI) • Cognition (MMSE) • Depression (GDS) • Executive functions (FAB) 4 weeks 4 weeks (postintervention) N = 72 Different types of dementia (Mild to Moderate) Institutionalized Median age: 84 Females: 80 MMSE: NR Reminiscence Therapy: N = 36 Individual sessions Twice a week during 8 weeks (45 min) • Depression (CSDD) 1 • Cognition (MMSE) 1 • Behavioral symptoms (NPI) 1 9 weeks 9 weeks (postintervention) N = 102 Different types of dementia (Mild to Severe) Institutionalized Mean age: 79.34 Females: 51% MMSE: 15.21 Reminiscence Therapy: N = 51 Group sessions Weekly sessions of 60 min over 8 weeks • Cognition (MMSE) • Depression (CSDD) 8 weeks 8 weeks (postintervention) N = 77 Different types of dementia (Mild to Moderate) Institutionalized Mean age: 79.04 Females: 48,1 MMSE: NR Reminiscence Therapy: N = 38 Group sessions Weekly sessions of 60 min over 8 weeks • Functional capacity (BI) • Behavioral symptoms (CAPE-BRS) 8 weeks 8 weeks (postintervention) N = 48 Different types of dementia (Mild to Moderate) Noninstitutionalized Mean age: 77.4 Females: 49.2 MMSE: NR Reminiscence Therapy: N = 268 Group sessions Weekly sessions of 120 min over 12 weeks and monthly maintenance sessions for further seven months • Anxiety (RAID)1 • Depression (CSDD)1 • Functional capacity (BADLS)1 • Quality of life (QoL-AD, EQ-5D)1 12 weeks 3 months (postintervention) and 10 months (follow-up) N = 103 Different types of dementia (Mild to Moderate) Noninstitutionalized Mean age: 73.6 Females: 69% MMSE: 23 Reminiscence Therapy: N = 53 Group sessions Weekly sessions of 60 min over 6 weeks 6 weeks 6 weeks (postintervention) N = 102 Different types of dementia (Mild to Severe) Institutionalized Mean age: 80.1 Females: 66% MMSE: NR Reminiscence Therapy: N = 43 Group sessions Weekly sessions of 30 min over 10 weeks Cognitive Stimulation: N = 20 Aromatherapy: N = 29 • Agitation (CMAI) • Depression (CSDDC) 10 weeks 10 weeks (postintervention) N = 80 Different types of dementia (Any severity) Noninstitutionalized Mean age: 82.1 Females: 58% MMSE: 17.5 Reminiscence Therapy: N = 32 Individual sessions Twice-weekly sessions of 30 min over 6 weeks Reminiscence Therapy: N = 32 Group sessions Twice-weekly sessions of 30 min over 6 weeks • Quality of life (QoL ladder) • Behavioral symptoms (NPI) 12 weeks 12 weeks (postintervention) ABMI Agitation Behavior Mapping Instrument, ADAS-COG Alzheimer Disease Assessment Scale-Cognitive, ABMI The Agitation Behavior Mapping Instrument, ACE-R Addenbrooke’s Cognitive Examination Revised, AD Alzheimer Disease, ADAS-Cog Alzheimer Disease Assessment Scale-Cognitive, ADCS-ADL Alzheimer’s Disease Cooperative Study—Activities of Daily Living Inventory, AGGIR Grille d’Autonomie Gérontologique-Groupes Iso-Ressources, AI Apathy Inventory, AMI Autobiographical Memory Interview, AMS Alzheimer’s Disease and Related Dementia Mood Scale, ARS Apathy Rating Scale, BADLS The Bristol Activities of Daily Living Scale, BANS-S Bedford Alzheimer Nursing Severity, BI Barthel Index, BMD Mood Disturbance Scale, BRS Behavior Rating Scale, CAPE Clifton Assessment Procedures for the Elderly, CAPE-BRS Clifton Assessment Procedures for the Elderly Behavior Rating Scale, CDR Clinical Dementia Rating Scale, CGI Clinical Global Impression, CMAI Cohen-Mansfield Agitation Inventory, CPS Cognitive Performance Scale, CSDD The Cornell Scale For Depression in Dementia, DAD Disablement Assessment for Dementia DEMQOL Dementia Quality of Life Instrument, DLAO The Daily Living Activities Observation, DOS Daily Observation Scale, EQ-5D European Quality of Life-5 Dimensions, FAB Frontal Assessment Battery, FRSSD Functional Rating Scale for Symptoms in Dementia, FRT Functional Reach Test, GAI Geriatric Anxiety Inventory, GCCT The Galton-Crovitz task, GDS Geriatric Scale of Depression, HADS Hospital Anxiety and Depression Scale, HHI Hert Hope Index, IS Interact Scale, LSL Life Satisfaction Scale, MADRS Montgomery-Asberg Depression Rating Scale, MAT Memory Alteration Test, MMSE Mini-Mental State Examination;MOSES Multidimensional Observation Scale for Elderly Subjects, NPI Neuropsychiatric Inventory, NR Not Reported, PES-AD The Pleasant Events Schedule.QCPR Quality of Caregiver–Patient Relationship, QoL Ladder Cantril Quality of Life Ladder, QoL-AD Quality of Life - Alzheimer’s Disease Scale, RAID Rating Anxiety in Dementia, RAVLT Rey Auditory Verbal Learning Test, SIWB Spirituality Index of Well-Being, SPMSQ Short Portable Mental State Questionnaire, SR Sharpened Romberg, TORS Todai-Shiki Observational Rating Scale, TUGT Timed Up and Go Test, UK United Kingdom, USA United States of America, VAS Visual Analog Scale, VD Vascular Dementia, VI Vitality Index, WAIS-III Wechsler Adult Intelligence Scale, ZBI Zarit Burden Interview 1Narrative synthesis aSociodemographic and clinical information reported only for patients included in the analyses. Quality assessment of the included studies The majority of studies in this review were assigned a high-risk rating, primarily attributed to biases stemming from deficiencies in the randomization process, the inherent challenge of blinding participants and raters to the received intervention, and the absence of an available protocol or a prespecified analysis plan. The risk of bias graph, with the ratings for each domain, is presented in Fig. 2. Risk of bias graph: review authors’ judgments about each risk of bias item are presented as percentages across all included studies Effectiveness of EOIs for dementia Apathy Three studies (n = 746) [26, 35, 36] with five comparisons assessed the effectiveness of reminiscence therapy in comparison to treatment-as-usual [26], group or individualized cognitive training [26] or no intervention [35, 36] for alleviating apathy in patients with mild-to-moderate AD. The assessment tools used in these studies included the Apathy Inventory [26] and the Apathy Evaluation Scale, which are self-administered [36] or clinician administered (AES-C) [35]. At the 3-month follow-up, no significant difference in apathy was found between the reminiscence therapy group and the control group (g = 0.54, 95% CI: -0.45 to 1.52, I2 = 97.01%) (Fig. 3). The study by Inel et al. (2019) [36] contributed all the heterogeneity. Excluding it from the analysis, the result was g = 0.10 (95% CI: -0.07 to 0.26), and heterogeneity ceased to be significant (I2 = 4.51%). The subgroup analysis by comparator, type of comparator (active vs. passive control) and institutionalization were not statistically significant (Additional File 3). Effects of reminiscence therapy vs. control on apathy Anxiety Two studies (n = 111) assessed the effectiveness of reminiscence therapy [39] and snoezelen [42] in comparison to treatment-as-usual [39] and music therapy [42] for reducing anxiety in patients with different types of dementia. The assessment tools employed varied across studies, with one utilizing the anxiety subscales of the INTERACT [42] and one utilizing the Neuropsychiatric Inventory (NPI) instruments [39]. No significant differences were found between the emotion-oriented approach group and the control group at the 3-month follow-up (g = 0.00, 95% CI: -0.37, 0.37, I2 = 1.28%) (Fig. 4). Two additional studies [47, 56] assessed anxiety but could not be included in the meta-analysis due to a lack of quantitative data (Additional File 4). EOIs vs. control on anxiety symptoms Agitation Three studies (n = 472) with five comparisons [34, 45, 58] assessed the effectiveness of reminiscence therapy in comparison to treatment-as-usual [45], art therapy [34], cognitive stimulation [58] or aromatherapy [58] for reducing agitation in institutionalized patients with different types of dementia. All studies assessed agitation using the Cohen-Mansfield Agitation Inventory (CMAI). No significant differences were found between the reminiscent and control groups at the 2.5-5.5-month follow-up (MD = -0.61, 95% CI: -4.12 to 2.91, I2 = 99.15%) (Fig. 5). Three additional studies [42, 46, 47] assessed agitation but could not be included in the meta-analysis due to a lack of quantitative data (Additional File 4). Reminiscence Therapy vs. control on agitation Behavioral symptoms Six studies (n = 1058) [26, 29, 39, 51, 53, 54] with 9 comparisons assessed the effectiveness of EOIs (i.e., Reminiscence Therapy and Snoezelen) in comparison with treatment-as-usual [26, 39, 51, 54], no intervention [53], group or individualized cognitive training [26] or activity sessions [29] for reducing behavioral symptoms in dementia patients. Four studies [26, 39, 51, 53] employed the NPI instrument, while the remaining two [29, 54] used the Behavior Rating Scale (BRS). At the 1-to-3-month follow-up, no significant difference in behavioral symptoms emerged between the emotion-focused approach group and the control group (g = -0.10, 95% CI: -0.28 to 0.09, I2 = 47.29%) (Fig. 6). The subgroup analyses, which considered variables such as the emotion-oriented approach, comparator, type of control, setting, age group, type of dementia, and severity of dementia, did not yield statistically significant differences (Additional File 3). However, the analysis differentiating between individual and group sessions revealed significant findings (p = 0.042); individual sessions were associated with a notable reduction in behavioral symptoms, with an effect size of g = -0.33 (95% CI: -0.63 to -0.02) and low heterogeneity (I2 = 26.45%) (Additional File 3). Visual examination of the funnel plot revealed no evidence of publication bias (Additional File 5). Seven additional studies [28, 31, 32, 42, 46, 50, 521Narrative synthesis] assessed behavioral symptoms but could not be included in the meta-analysis due to a lack of quantitative data (Additional File 4). Effects of EOIs vs. control on behavioral symptoms Cognitive function Fifteen studies (n = 1802) [26, 29, 33, 36, 37, 39, 40, 43, 44, 48, 49, 51, 53, 55, 57] with 19 comparisons assessed the effectiveness of EOIs (i.e., Reminiscence Therapy and Snoezelen) in comparison with treatment-as-usual [26, 39, 43, 49, 51, 55], no intervention [33, 36, 40, 44, 48, 53, 57], group or individualized cognitive training [26] or activity sessions [29] for improving cognition in patients with different types of dementia. Two studies used the Alzheimer Disease Assessment Scale-Cognitive (ADAS-COG) [26, 39], while the remaining studies used the MMSE [29, 33, 36, 37, 40, 43, 44, 48, 49, 51, 53, 55, 57]. After 1–6 months of follow-up, a significant increase in cognitive function was found, favoring the group treated with EOIs (g = 0.43, 95% CI: 0.12 to 0.75, I2 = 89.40%) (Fig. 7). The subgroup analysis by emotion-oriented approach, type of control, setting, type of sessions (group vs. individual), type of dementia, age group or dementia severity were not statistically significant (Additional File 3). The subgroup analysis by comparator was not statistically significant. However, the effect on cognitive function was only statistically significant in the subgroup of studies comparing EOIs to no intervention (g = 0.88, 95% CI: 0.13 to 1.63, I2 = 93.35%) but not in the studies comparing with cognition-oriented interventions (g = 0.04, 95% CI: -0.18 to 0.25, I2 = 2.63%), stimulation-oriented interventions (g = 0.37, 95% CI: -0.04, 0.77, I2 = 4.00%) or treatment-as-usual procedures (g = 0.17, 95% CI: -0.06 to 0.40, I2 = 48.47%). Meta-regression analyses explored whether participants’ mean age, sex, or baseline cognitive function (MMSE score) influenced the effectiveness of EOIs on cognitive outcomes. None of these variables significantly moderated the results (age: p = 0.228; sex: p = 0.519; MMSE: p = 0.428). Visual examination of the funnel plot revealed no evidence of publication bias (Additional File 5), the trim-and-fill analysis did not require any additional studies, and Egger tests showed no evidence of a small-study effect (p = 0.09). Six additional studies [28, 38, 42, 46, 47, 52] assessed cognition but could not be included in the meta-analysis due to a lack of quantitative data (Additional File 4). Effects of EOIs vs. control on cognitive function Depression Sixteen studies (n = 2118) [26, 33, 35, 37, 39, 40, 42, 44, 45, 48, 49, 51, 53–55, 58] involving 20 comparisons assessed the effectiveness of EOIs (i.e., Reminiscence Therapy and Snoezelen) in comparison with treatment-as-usual [26, 37, 39, 45, 49, 54, 55], no intervention [33, 35, 40, 44, 48, 53], group or individualized cognitive training [26, 58], music therapy [41] and aroma therapy [58] for alleviating depressive symptoms in patients with different types of dementia. Eight studies used the Cornell Scale for Depression in Dementia (CSDD) [39, 40, 44, 45, 51, 54, 55, 58], six used the Geriatric Depression Scale (GDS) [33, 35, 37, 48, 53], and one used the Montgomery-Asberg Depression Rating Scale (MADRS) [26]. Two other studies used observation instruments such as INTERACT [41] and the Multidimensional Observation Scale for Elderly Subjects (MOSES) [49]. After the 1-9-month follow-up, no significant difference in depressive symptoms was found between the emotion-focused approach group and the control group (g = -0.28, 95% CI: -0.58 to 0.02, I2 = 90.30%) (Fig. 8). The subgroup analysis by comparator was statistically significant (p = 0.01) (Additional File 3). The effect of EOIs on depressive symptoms was statistically significant only compared to no intervention (g = -0.85, 95% CI: -1.33 to -0.36, I2 = 81.63%) but not compared to stimulation-oriented interventions (g = -0.12, 95% CI: -0.91 to 0.67, I2 = 60.63%), cognition-oriented interventions (g = 0.12, 95% CI: -0.20 to 0.43, I2 = 54.81%) or treatment-as-usual (g = -0.09, 95% CI: -0.52 to 0.33, I2 = 91.15%). Similarly, the subgroup analysis by severity was also statistically significant (p = 0.00). The effect of EOIs on depressive symptoms was not statistically significant in patients with mild-to-moderate (g = -0.39, 95% CI: -0.77 to 0.00, I2 = 92.09%) or mild-to-severe dementia (g = -0.19, 95% CI: -0.67, 0.29, I2 = 67.98%). The subgroup of patients with moderate-to-severe dementia increased their depressive symptoms after EOIs (g = 0.32, 95% CI: 0.10 to 0.54, I2 = 0.01). Meta-regression analyses explored whether participants’ mean age, sex, or baseline cognitive function (MMSE score) influenced the effectiveness of EOIs on depressive symptoms. None of these variables significantly moderated the results (age: p = 0.706; sex: p = 0.706; MMSE: p = 0.876). Visual examination of the funnel plot revealed no evidence of publication bias (Additional File 5), the trim-and-fill analysis did not require any additional studies, and Egger tests showed no evidence of a small-study effect (p = 0.692). Five additional studies [42, 46, 47, 52, 56] assessed depressive symptoms but could not be included in the meta-analysis due to a lack of quantitative data (Additional File 4). Effects of EOIs vs. control on depressive symptoms Functional abilities Four studies (n = 952) [26, 27, 39, 54] involving 7 comparisons assessed the effectiveness of reminiscence therapy in comparison with treatment-as-usual [26, 39, 54], no intervention [27], group or individualized cognitive training [26] or counseling [27] for improving functional abilities in patients with different types of dementia. One study used the Disability Assessment for Dementia (DAD) [26], one used the Activity of Daily Living Scale (ADL) [27], and the remaining two used the Barthel Index (BI) [39, 54]. After 2–3 months of follow-up, no significant difference in functional abilities were found between the Reminiscence Therapy group and the control group (g = -0.92, 95% CI: -2.26 to 0.41, I2 = 98.74%) (Fig. 9). The subgroup analysis by comparator was statistically significant (p = 0.00) (Additional File 3). The effect of EOIs on functional abilities was statistically significant only compared to no intervention (g = -2.25, 95% CI: -2.88 to -1.61) and counseling (g = -4.62, 95% CI: -5.55 to -3.68) but not compared to treatment-as-usual (g = 0.04, 95% CI: -0.28 to 0.41, I2 = 49.93%) or cognition-oriented interventions (g = 0.03, 95% CI: -0.18 to 0.25, I2 = 0.51%). The subgroup analyses by type of dementia, age group, setting and type of control were not statistically significant. Visual examination of the funnel plot revealed no evidence of publication bias (Additional File 5). Effects of Reminiscence Therapy vs. Control on Functional Abilities Quality of life Five studies (n = 1400) [26, 27, 37, 40, 45] involving eight comparisons assessed the effectiveness of reminiscence therapy in comparison with treatment-as-usual [26, 37, 45], no intervention [27, 40], group or individualized cognitive training [26] or counseling [27] for improving health-related quality of life in patients with different types of dementia. Five studies used the Quality of Life-Alzheimer’s Disease Scale (QoL-AD) [26, 27, 40, 45], and the remaining study used the Self-Reported Quality of Life Scale (SRQoL) [27]. After 2–6 months of follow-up, a significant increase in health-related quality of life was found, favoring the group treated with reminiscence therapy (g = 0.29, 95% CI: 0.05 to 0.53, I2 = 75.77%) (Fig. 10). The subgroup analysis by comparator was statistically significant (p = 0.01) (Additional File 3). The effect of reminiscence therapy on health-related quality of life was statistically significant only compared to no intervention (g = 0.66, 95% CI: 0.28 to 1.04, I2 = 6.33%) but not compared to counseling (g = 0.50, 95% CI: -0.01 to 1.02). treatment-as-usual (g = 0.27, 95% CI: -0.14 to 0.68, I2 = 86.72%) or cognition-oriented interventions (g = -0.02, 95% CI: -0.23 to 0.20, I2 = 4.06%). Similarly, the subgroup analysis by setting showed that the effect on quality of life was statistically significant only for institutionalized patients (g = 0.62, 95% CI: 0.43, 0.81, I2 = 4.33%). The subgroup analyses by type of dementia, type of session (group vs. individual) and type of control were not statistically significant. Visual examination of the funnel plot revealed no evidence of publication bias (Additional File 5). Two additional studies [30, 56] assessed quality of life but could not be included in the meta-analysis due to a lack of quantitative data (Additional File 4). Effect of Reminiscence Therapy vs. Control on Quality of Life Executive functions Two studies (n = 333) [37, 53] assessed the effectiveness of reminiscence therapy in comparison with treatment-as-usual for improving executive functions in patients with dementia using the Frontal Assessment Battery. After the 1-3-month follow-up, no significant difference in frontal symptoms was found between the Reminiscence Therapy group and the control group (g = 0.21, 95% CI: -0.01 to 0.43, I2 = 1.08%) (Fig. 11). One additional study [38] assessed executive functions but could not be included in the meta-analysis due to a lack of quantitative data (Additional File 4). Effects of remission therapy vs. control therapy on frontal symptoms Discussion Summary of results In this SR and MA, we evaluated the effectiveness of emotion-oriented interventions, particularly Reminiscence Therapy and Snoezelen, for managing symptoms of dementia. Our findings revealed significant improvements in cognition, depressive symptoms, quality of life, and functional abilities when these interventions were compared to no intervention. These emotion-oriented interventions, however, had no significant impact on outcomes such as apathy, anxiety, agitation, behavioral symptoms, or executive functions. While these findings suggest that EOIs might be considered in contexts where well-established interventions, such as cognitive-based interventions, are not available, the evidence is preliminary, given the low quality and high heterogeneity of the included studies. The previous literature has consistently highlighted both the potential benefits and significant drawbacks of these interventions, including the presence of low-quality studies and persistent heterogeneity. This suggests that while interventions may positively affect dementia symptoms, the research is often compromised by methodological flaws and the absence of well-defined protocols for application, thereby undermining the robustness of these conclusions. The initial comprehensive review of these interventions published in 2000 noted that while positive outcomes were observed, many studies were compromised by methodological limitations [18]. Despite advances over two decades, including numerous RCTs and SRs, these challenges remain prevalent. A recent SR by Saragih et al. (2022) [60] emphasized that reminiscence therapy improves cognitive function and quality of life while decreasing depression and neuropsychiatric symptoms in dementia patients. However, they advocate for the development of a global standard protocol to harmonize research efforts and application practices [60]. Specifically, in the field of depression, Liu et al. (2022) [61] reported significant improvements in remission rates and quality of life following reminiscence therapy. However, they highlighted the difficulty of comparing intervention effects across studies due to nonstandardized procedures [61]. Similar issues have been noted in studies on Snoezelen, where a lack of consensus on session frequency, duration, and overall intervention length has been reported [62]. Given these varied intervention characteristics and the heterogeneous findings, we conducted subgroup analyses by type of emotion-oriented approach when sufficient data were available. However, these analyses did not reveal significant differences between the interventions, suggesting that neither approach is consistently superior. Moreover, the predominance of studies focusing on Reminiscence Therapy suggests a need for further research comparing it directly with Snoezelen to determine which emotion-oriented approach might be more beneficial for specific patient profiles. Understanding these differences could help clinicians tailor interventions more effectively, potentially leading to more robust and personalized dementia care strategies. Despite the positive outcomes frequently reported in SRs, our analysis highlights a critical gap in the literature: the variation in the effectiveness of EOIs depending on the comparison conditions used has not been thoroughly assessed. In our study, compared with no intervention, reminiscence therapy and Snoezelen showed some significant benefits, suggesting their potential utility in scenarios devoid of alternative treatment options. However, their effectiveness was less pronounced than that of other active interventions, such as cognitive-and-stimulation-oriented interventions or standard treatment protocols. This finding aligns with the results of a previous meta-analysis by Pinquart et al. (2012) [63], which also revealed that the impact of regeneration therapy on psychosocial outcomes varied significantly, with relatively weaker effects observed in studies employing active comparators, although it did not focus specifically on patients with dementia. Implications for policy and practice Evidence from our study underscores that while emotion-oriented therapies such as Reminiscence Therapy can be beneficial, they do not consistently outperform traditional therapeutic approaches, such as structured cognitive therapies. This finding is crucial for clinical decision-making and resource allocation, emphasizing the need to understand the relative efficacy of different interventions. Our analysis was extended to evaluate the influence of patient and contextual factors, including age, sex, dementia type, severity of cognitive symptoms, and care setting, on treatment effectiveness. Despite extensive subgroup analyses and meta-regression efforts, high heterogeneity persisted across the studies, which could not be fully explained by these variables. However, the analysis concerning the severity of dementia symptoms provided statistically significant insights. The effectiveness of emotion-oriented therapies on depressive symptoms is significantly moderated by the stage of dementia, with beneficial effects in mild-to-moderate stages and potentially adverse effects in more severe stages. These findings highlighted the critical importance of tailoring therapeutic interventions to the individual characteristics and conditions of patients, ensuring that patients receive the most appropriate and potentially effective care tailored to their specific needs. Identifying the specific circumstances under which EOIs are most effective is vital, particularly in resource-scarce settings where strategic focus can enhance treatment efficacy and optimize resource allocation. To this end, we conducted subgroup analyses comparing individual and group sessions where sufficient data were available. These analyses revealed that individual sessions significantly reduced behavioral symptoms, and although not significantly, they also tended to yield better outcomes for depression, cognitive function, and quality of life. This suggests that individual sessions might be more effective in certain respects. However, the literature presents mixed results. Cammisuli et al. (2022) [64] concluded that reminiscence therapy administered in individual or group sessions at least once a week for 30–35 min over a period of 12 weeks was effective in supporting global cognition, ameliorating depression, and improving specific aspects of quality of life in elderly people with Alzheimer’s disease. Conversely, an SR by Liu et al. (2022) [61] suggested that group therapy not only surpasses individual therapy in overall effectiveness but also in cost-effectiveness, as it consumes fewer resources and demands less time from healthcare professionals. Given these discrepancies, more research is needed to establish under what conditions each approach—individual versus group—works best. The integration of information and communication technology in Reminiscence Therapy has been proposed as a strategy to boost its effectiveness. Among the studies we reviewed, only one used digital resources [36]. Inel et al. (2019) [36] demonstrated that reminiscence therapy facilitated by internet-based videos can enhance cognitive functions and reduce apathy in older adults with mild dementia related to Alzheimer’s disease. Similarly, a pilot study by Moon and Park (2020) [65] explored the use of an Android application and digital content in Reminiscence Therapy, which not only improved mood but also facilitated social interactions among dementia patients. Despite these promising results, the use of digital tools in regeneration therapy is still an evolving field. These technologies hold significant potential for customization, allowing therapists to use software to create personalized digital photo albums, music playlists, and virtual reality experiences that resonate deeply with each patient’s personal history and cognitive needs [19]. This tailored approach could enrich the emotional and cognitive impact of the sessions, making therapy more engaging and potentially more effective. However, integrating these technologies into existing therapeutic practices will require addressing several key challenges. These include personal and contextual factors that affect both patients and providers, the perceived value and benefit of the technology, the design and content of the digital health interventions to ensure usability and engagement, and the digital literacy and confidence of users [66]. Policies supporting digital health innovation could play a crucial role in overcoming these obstacles, ensuring that technological advancements in therapy are both effective and widely accessible. Additionally, our findings could serve as a foundation for updating mobile clinical decision support systems regarding psychosocial interventions for dementia, such as the PSICODEM app [67]. Limitations Despite the strengths of including studies performed in several different countries worldwide, which aids in the generalizability of our findings, this SR has several limitations that warrant consideration. The selection of studies was restricted to those published in Spanish and English, potentially excluding relevant research available in other languages. Additionally, the exclusion of gray literature, such as these and other nonpeer reviewed works, might have led to the omission of pertinent studies. Furthermore, while our intent was to evaluate the various emotion-oriented approaches recommended by the APA, our analysis was predominantly focused on Reminiscence Therapy, with fewer studies examining Snoezelen and only one on Validation Therapy, thereby limiting the generalizability of our findings across all EOIs. The studies included also presented several methodological limitations, such as deficiencies in the randomization process, challenges in blinding participants and raters to the intervention, and the absence of an available protocol or prespecified analysis plan, all of which could influence the results. Overall, these issues reflected a high or unclear risk of bias in many of the included studies, which may have affected the robustness of the pooled findings. Furthermore, significant heterogeneity was observed that could not be accounted for by subgroup analysis or meta-regressions, suggesting caution in interpreting these results. The varied measures and tools used to assess outcomes across studies further complicate the ability to establish direct comparisons. This review assessed only the short-term effects of the interventions. The long-term effects remain unexplored and should be addressed in future research through more rigorous, longitudinal studies that improve on the noted methodological deficiencies. Last, the literature search was conducted up to January 19, 2023; consequently, more recent studies were not captured. While this represents a potential limitation, it does not diminish the relevance of the current findings, which synthesize the best available evidence at the time. Future updates incorporating newer studies will help confirm or refine these conclusions as additional data become available. Future research The findings from this SR led to several key considerations for future research in dementia care. Identifying which patients and specific circumstances are best suited for EOIs remains a priority. Future studies should aim to standardize intervention protocols, such as specifying the frequency, duration, and intensity of sessions, to reduce variability and enhance the comparability of results across studies. This standardization will also facilitate the tailoring of interventions to better meet individual patient needs and optimize healthcare resources. Moreover, there is a crucial need to develop robust comparative studies that evaluate emotion-oriented therapies compared with other established therapeutic modalities. These comparative studies should include a variety of clinical endpoints to clearly define the role of these therapies within the broader spectrum of dementia care options. Such studies will clarify the role of these therapies in the wider landscape of dementia care options, ensuring that treatment decisions are supported by solid evidence. Ultimately, by addressing these gaps, future research can refine the therapeutic landscape, ensuring that all patients have access to the most suitable and effective treatments available. Conclusion Emotion-oriented therapies, particularly Reminiscence Therapy, represent a promising addition to conventional dementia treatments, offering valuable alternatives, especially in settings where traditional options may be limited. These interventions not only address cognitive deficits but also significantly enhance the emotional and psychological well-being of people with dementia, promoting a more holistic approach to care. Our findings highlight the effectiveness of these therapies in improving quality of life and underscore the urgent need for additional research. Future studies should aim to further refine these interventions, evaluate their long-term effects, and develop comprehensive guidelines for their implementation. Such guidelines should be tailored to meet diverse clinical contexts and the unique needs and profiles of patients, ensuring that all people with dementia have access to the most effective and appropriate treatments. Supplementary Information Supplementary Material 1. Supplementary Material 2. Supplementary Material 3. Supplementary Material 4. Supplementary Material 5. Acknowledgements The authors would like to thank Leticia Rodríguez and Carlos González for their help with the database search and acquisition of the relevant papers. Authors’ contributions Study concept and design: Marta Aymerich, Noemí Robles and Carme Carrion. Screening, quality assessment and data extraction: Andrea Duarte-Díaz, Yolanda Álvarez-Pérez, Vanesa Ramos-García and Lilisbeth Perestelo-Pérez. Analysis and interpretation: Andrea Duarte-Díaz, Yolanda Álvarez-Pérez, Vanesa Ramos-García, Lilisbeth Perestelo-Pérez, Marta Aymerich, Noemí Robles and Carme Carrion. All authors contributed to the writing and editing of the manuscript and agreed to the final manuscript. Funding This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. Data availability All data generated or analyzed during this study are included in this published article and its Additional information files. Declarations Ethics approval and consent to participate Not applicable. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Material 1. Supplementary Material 2. Supplementary Material 3. Supplementary Material 4. Supplementary Material 5. Data Availability Statement All data generated or analyzed during this study are included in this published article and its Additional information files.